Australia's EchoIQ rises on commercial licensing deal
25/01/2024 24:37
** Shares of EchoIQ Ltd EIQ.AX up 3.7% at A$0.14, set for
best day since Jan 17, if gains hold
** Medical technology firm says it entered into a commercial
licensing agreement with Respiri Ltd RSH.AX
** Says agreement to apply co's AI-backed EchoSolv
cardiovascular solutions to Respiri's remote patient monitoring
user base
** EchoIQ stock down 20.6% YTD, as of last close
(Reporting by Ayushman Ojha in Bengaluru)
((Ayushman.ojha@thomsonreuters.com;))
Recent news on EchoIQ
See all newsAustralia's EchoIQ gains most in nearly 3 months after FDA update
Brief: EchoIQ Says FDA Raises No Concerns About Echosolv HF Technology Or Core Functionality
Australia's EchoIQ heads for worst week in seven years after US FDA setback
Australia's Echo IQ logs worst day in seven years after FDA setback
Brief: EchoIQ Requests Trading Halt